Board of Directors

Ms Christensen is a Partner and Co-Head of Healthcare at The Vistria Group.  Prior to joining Vistria, Ms. Christensen was a Vice President at NewSpring Capital, a middle market private equity firm with a family of funds, including a dedicated healthcare fund. Prior to NewSpring, Ms. Christensen was an investment professional with the Gores Group and Calder Capital Partners. Ms. Christensen began her career as a healthcare consultant with the Huron Consulting Group.

Ms. Christensen currently serves on the Board of Directors of Behavioral Health Group, Chiro One, Supplemental Healthcare, Beacon Specialized Living, and Sandstone Care.  She previously served on the boards of St. Croix Hospice, Angel Medflight, and Alacura.

Ms. Christensen received a B.S. from Northwestern University summa cum laude and an M.B.A. from The University of Chicago Booth School of Business where she was an Andrew Alper Merit Scholar.

Geoff is a Partner of Two Sigma Impact, the private equity business of Two Sigma. Prior to Two Sigma, Geoff worked in the private equity funds of Lee Equity Partners, TPG Capital and Bain Capital and began his career as a consultant at Bain & Company. Geoff has been a director of several companies, including Circle of Care, Solaris Health, Summit BHC, Westfall Technik, Eating Recovery Centers, PDR Networks, Key Health, Paragon Industries, and Aptalis Pharma. Geoff was a faculty lecturer at Stanford Business School and is a member of the Board of Directors of the Healthcare Private Equity Association. Geoff is also a co-founder of Inspire Inc, a volunteer consulting non-profit organization, where he continues to serve as a director. Geoff received an M.B.A. from Stanford Business School and a B.A. in Engineering Sciences cum laude from Dartmouth College.

 Thomas “TJ” Carella joined Warburg Pincus in 2016. Based in New York, he serves as a Managing Director and is Head of the Healthcare Group. He is a Director of Aetion, Alignment Healthcare, Polyplus Transfection, Quantum Health, SOC Telemed, Summit Health, Vertice Pharma and WebPT. Prior to joining Warburg Pincus, TJ was a Partner in the Merchant Banking Division of Goldman Sachs and Global Head of the division’s Private Equity activities in the Healthcare sector. While at Goldman Sachs, he led, or was actively involved in several investments across Life Sciences, Healthcare Services and Healthcare Information Technology. He earned his bachelor’s degree from Harvard College and his M.B.A. from Harvard Business School. 

Andrew Cavanna is a Partner and Co-Head of Healthcare at Apax Partners. He joined Apax in 2017 and is based in New York. Andrew serves on the board of Eating Recovery Center (ERC), Kepro and InnovAge and previously served on the board of Genex. Andrew is also a Member of the Cornell College of Arts and Sciences Advisory Council and Board Member of School in the Square, a charter school providing elementary and middle school education to the Washington Heights community in New York City.

Prior to joining Apax, Andrew spent eleven years at Vestar Capital Partners where he was a Managing Director and Co-Head of the Healthcare Sector. At Vestar, Andrew was involved with a number of investments including Press Ganey, Essent Healthcare, StayWell, Joerns Healthcare, Sunrise Medical, Institutional Shareholder Services (ISS) and Veritas Collaborative. Andrew came to Vestar in 2006 from The Blackstone Group. Prior to Blackstone, Andrew was a Senior Associate at JPMorgan Partners. Andrew started his career as an Analyst in Leveraged Finance at Merrill Lynch.

Andrew holds an MBA from Columbia Business School and a BA, cum laude, in Economics and Government from Cornell University.

Mr. Crosby joined Nautic Partners in 2001.  Mr. Crosby focuses on healthcare investments and currently serves on the Boards of Directors of Mikart Holdings, Integrated Homecare Services, Nystrom Associates and Pyramid Healthcare. Mr. Crosby is also a member of Nautic’s Investment and Executive Committees.

Mr. Crosby received a BA from Boston College and an MBA from the Harvard Business School.  Mr. Crosby is a board member of Blue Cross Blue Shield of RI where he is on the Compensation and Finance Committees.

Fazle Husain is Head of US Healthcare at CVC Capital Partners, a global private equity firm with a network of 23 offices and over 400 employees throughout Europe, Asia and US. The CVC Group manages over $50 billion of assets. Prior to joining CVC Capital, Fazle was a Managing Director at Metalmark Capital from 2007-2016, and was responsible for leading their effort in healthcare. Before Metalmark Capital, he was with Morgan Stanley & Co. in the private equity business, where he spent 18 years. He has a successful track record of investing in healthcare companies for over 25 years, including investments in the healthcare service, medical device, specialty pharmaceuticals and healthcare information technology sectors. He has invested in and served on the Boards of several private and public companies including ExamWorks, MedRisk, Icario, Allscripts (MDRX), Cross Country Healthcare (CCRN), The Medicines Company (MDCO), Cardiac Pathways (sold to Boston Scientific), Suros Surgical (sold to Hologic), Healthstream (HSTM), Cytyc Corp (sold to Hologic), Aegis Sciences, and Vanguard Healthcare Systems (sold to Tenet). He was the Chairman of the Board of Healogics (2008-2014), and was the Chairman of the Board of Collagen Matrix (2014-2016).

Mr. Husain received an Sc.B. degree in Chemical Engineering from Brown University, and an M.B.A. from Harvard Business School. He is on the Board of Advisors for The School of Engineering at Brown University. He lives in New York City, with his wife and three children.

Ms. Kim joined CD&R in 2008 and is a member of the Firm’s Inclusion Committee. She has played a key role in the Firm’s investments in Aster Insights (fka: M2GEN), Covetrus, Diversey, Gentiva, HD Supply, Inizio, naviHealth, ServiceMaster, and Sharp. Previously, she held positions at private equity firms Metalmark Capital and McCown De Leeuw & Co. and worked in the investment banking division of Goldman Sachs & Co. Ms. Kim has a J.D. from Harvard Law School, an M.B.A. from Harvard Business School, and a B.A. in economics and political science from Yale University.

Ben joined Frazier Healthcare Partners in 2006. He represents Frazier on the boards of CSafe Global, Caravel Autism Health, Comprehensive Pharmacy Services, Matrix Medical Network, Parata Systems, SunMed and United Derm Partners. Ben has been responsible for Frazier’s successful investments in Ascension Orthopedics, DSI Renal, Golden State Medical Supply, Laboratory Supply Company and Northfield Medical.

Prior to Frazier, Ben was at Morgan Stanley Capital Partners (MSCP), focusing on investing in the healthcare sector. Before joining MSCP, he was in the Healthcare Investment Banking Group of Morgan Stanley.

Ben is also an Advisor for American Corporate Partners, a nationwide mentoring program dedicated to helping veterans transition to the private sector.

Ben received his M.B.A from the Tuck School of Business at Dartmouth and his B.B.A. in Finance and Computer Applications from the University of Notre Dame.

Mr. O’Leary is a General Partner, having joined WCAS in 2015. Prior to joining WCAS, Mr. O’Leary worked at JLL Partners for over six years, focused primarily on healthcare investments. Earlier in his career, he worked in the Mergers and Acquisitions group at Merrill Lynch.

Mr. O’Leary received a B.A. from Washington and Lee University.

Doug is a Managing Director with DW Healthcare Partners. His investment and transaction experience includes bio-analytical/immune-analytical service laboratories, institutional and specialty pharmacies, medical device manufacturers in the cardiac and orthopedic markets, physician practice management companies, elder care service providers and clinical research organizations.

Before joining DW Healthcare Partners, Doug worked for Bain & Company. While there, Doug led strategic due diligence efforts as part of Bain’s Private Equity Group. Prior to joining Bain’s Private Equity Group, Doug advised Bain’s commercial clients in the consumer products and food service industries.

Doug received a Bachelors degree from Cornell University and an MBA with Distinction from Harvard Business School, and previously sat on the Harvard Business School Alumni Board of Directors.

Anushka Sunder is a Managing Director in Blackstone’s Private Equity Group. Ms. Sunder focuses primarily on Blackstone’s private equity investments in healthcare and technology. Ms. Sunder serves on the Board of Directors of Blue Yonder, CARD, HealthEdge, Optiv, Precision Medicine Group, and TeamHealth and has also been actively involved in the execution of Blackstone’s investments in InComm, NCR, Outerstuff, and Signature Aviation. She is co-chair of the Blackstone Women’s Initiative task force and on the Blackstone Charitable Foundation Leadership Council.  Before joining Blackstone in 2013, Ms. Sunder was an associate at TPG Capital and an analyst at Goldman Sachs in the Financial Institutions Group. Ms. Sunder received an AB in Economics from Harvard College, where she graduated magna cum laude and Phi Beta Kappa, and an MBA from Harvard Business School. She is also a member of the Corporate Leaders Program at the Council on Foreign Relations.

Prior to joining HEP 14 years ago, Dave was a Vice President for Susquehanna Growth Equity, a private equity group focused on growth stage technology companies. He was formerly the President and Chief Operating Officer of Onward Healthcare, Inc., a Welsh, Carson, Anderson & Stowe portfolio company. Prior to Onward, Dave was an Executive Vice President of Pinnacor, Inc., a General Atlantic portfolio company, which went public.

Dave is currently on the board of directors of Alivia Analytics, Catapult Health, Intraprise Health, Jet Health, NOCD, PatientIQ and Veterinary Innovative Partners. He is on the faculty at Columbia Business School. In addition, Dave is also a member of the Healthcare Initiative Advisory Board at Harvard Business School. Dave is a distinguished graduate of the United States Military Academy and holds an MBA from Harvard Business School.

Katherine Wood is a Partner with TPG Capital based in San Francisco, where she focuses on investments in the healthcare sector. She currently serves on the Boards of Convey Health Solutions, LifeStance Health and Ellodi, and was previously on the Boards of Adare, AskBio, and Neogene. She was also involved in TPG’s investments in Allogene, Aptalis, EnvisionRx, IASIS Healthcare, and Par Pharmaceutical and in founding TPG’s Women’s Affinity Group. She currently serves on the Board of Catalight, a non-profit healthcare organization.

Prior to joining TPG in 2009, Katherine worked in healthcare investment banking at Goldman, Sachs & Co. Katherine received a BS with Honors in molecular and cell biology from Stanford University, where she was on the varsity field hockey team, and an MBA with Distinction from Harvard Business School.